Autolus Therapeutics PLC Sponsored ADR (NASDAQ:AUTL - Get Free Report)'s share price rose 7.1% during trading on Monday . The stock traded as high as $2.63 and last traded at $2.65. Approximately 779,759 shares changed hands during trading, a decline of 50% from the average daily volume of 1,563,942 shares. The stock had previously closed at $2.47.
Wall Street Analyst Weigh In
A number of research firms recently commented on AUTL. Needham & Company LLC reaffirmed a "buy" rating and issued a $10.00 price target on shares of Autolus Therapeutics in a report on Thursday, June 12th. Wells Fargo & Company lowered their price target on shares of Autolus Therapeutics from $8.00 to $6.00 and set an "overweight" rating on the stock in a report on Friday, March 21st. Finally, Truist Financial lowered their price target on shares of Autolus Therapeutics from $11.00 to $10.00 and set a "buy" rating on the stock in a report on Tuesday, April 1st. Five equities research analysts have rated the stock with a buy rating, Based on data from MarketBeat, the company currently has an average rating of "Buy" and a consensus target price of $9.32.
View Our Latest Stock Analysis on AUTL
Autolus Therapeutics Trading Down 0.8%
The company has a market cap of $644.06 million, a P/E ratio of -2.75 and a beta of 1.81. The business's fifty day moving average is $2.02 and its 200 day moving average is $1.89.
Autolus Therapeutics (NASDAQ:AUTL - Get Free Report) last released its quarterly earnings data on Thursday, May 8th. The company reported ($0.26) earnings per share for the quarter, missing analysts' consensus estimates of ($0.24) by ($0.02). The company had revenue of $8.98 million for the quarter, compared to analyst estimates of $1.59 million. As a group, research analysts expect that Autolus Therapeutics PLC Sponsored ADR will post -0.94 EPS for the current fiscal year.
Institutional Inflows and Outflows
A number of hedge funds have recently bought and sold shares of the business. Forefront Wealth Management Inc. purchased a new position in Autolus Therapeutics in the 2nd quarter valued at approximately $61,000. Avanza Fonder AB grew its stake in Autolus Therapeutics by 151.6% in the 2nd quarter. Avanza Fonder AB now owns 53,522 shares of the company's stock valued at $122,000 after buying an additional 32,246 shares in the last quarter. Atle Fund Management AB grew its stake in Autolus Therapeutics by 130.5% in the 2nd quarter. Atle Fund Management AB now owns 1,105,461 shares of the company's stock valued at $2,520,000 after buying an additional 625,817 shares in the last quarter. Jane Street Group LLC grew its stake in Autolus Therapeutics by 809.4% in the 1st quarter. Jane Street Group LLC now owns 102,493 shares of the company's stock valued at $159,000 after buying an additional 91,222 shares in the last quarter. Finally, Armistice Capital LLC grew its stake in Autolus Therapeutics by 19.6% in the 1st quarter. Armistice Capital LLC now owns 11,000,000 shares of the company's stock valued at $17,050,000 after buying an additional 1,800,000 shares in the last quarter. 72.83% of the stock is currently owned by hedge funds and other institutional investors.
About Autolus Therapeutics
(
Get Free Report)
Autolus Therapeutics plc, a clinical-stage biopharmaceutical company, develops T cell therapies for the treatment of cancer and autoimmune diseases. The company's clinical-stage programs include obecabtagene autoleucel (AUTO1), a CD19-targeting programmed T cell investigational therapy that is in Phase 1b/2 clinical trial for the treatment of adult ALL; AUTO1/22, which is in a Phase 1 clinical trial in pediatric patients with relapsed or refractory ALL; AUTO4, a programmed T cell investigational therapy for the treatment of peripheral T-cell lymphoma targeting TRBC1 and TRBC2; AUTO6NG, a programmed T cell investigational therapy targeting GD2 in development for the treatment of neuroblastoma; and AUTO8, a product candidate to treat multiple myeloma.
Featured Stories
Before you consider Autolus Therapeutics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Autolus Therapeutics wasn't on the list.
While Autolus Therapeutics currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Unlock the timeless value of gold with our exclusive 2025 Gold Forecasting Report. Explore why gold remains the ultimate investment for safeguarding wealth against inflation, economic shifts, and global uncertainties. Whether you're planning for future generations or seeking a reliable asset in turbulent times, this report is your essential guide to making informed decisions.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.